

Date: 24/3/2021

Draft V6.4

Information on the status of adoption of national guidance on liothyronine prescribing by CCGs in England

Contents

Purpose of the paper and background information	2
CCG Prescribing status review and basis of the preparation of this data	3
Summary of findings	3
Recommendations	5
Appendix 1/ List of the problematic CCGs, categorised by issue, A-H	6
Category A	6
Category B	7
Category C	8
Category D	10
Category E	10
Category F	10
Category G	11
Category H	12
Appendix 2/ CCGs policy review summary - all CCGs in England	13
Appendix 3/ List of CCGs where The Thyroid Trust have received reports of difficulties, directly from individual patients.	53
References	56

Purpose of the paper and background information

The purpose of this paper is to highlight the ongoing issues with unfair and inconsistent prescribing policies in a majority of areas across England, for the thyroid hormone treatment, liothyronine and to push for urgent remedial action at a national level, to end the harm which is still being done to patients, due to treatment still being unreasonably withheld in at least 52% of CCGs.

Previous reports published in 2018 and 2020 (references A and B) have highlighted this issue, which appears to have been caused solely by the high price of this old generic medicine to the NHS, which pays very much more than healthcare providers in other countries, for reasons which remain unclear. The original sole licence holder is still under investigation by the CMA and have been found provisionally guilty of abusing their dominant market position. Prices have very slowly dropped by around half since 2016, but in March 2021 the Drug Tariff price for liothyronine remains inexplicably around five times more expensive than in comparable countries such as France and Germany.

The following pages set out:

1. The status of adoption into CCG policy of the NHSE Regional Medicines Optimisation Committee (RMOC) liothyronine prescribing guidance, published June 2019. (2)
2. The extent current local CCG policies meet the national guidelines for liothyronine, referencing: NHS England Medicines Value Programme recommendations, November 2017, RMOC liothyronine prescribing guidance, June 2019, NICE NG145 Guideline Thyroid Disease: Assessment and Management published November 2019 (3) and Lord Bethell's statement regarding further NHS England guidance, February 2020 (4).
3. A comprehensive review of all CCGs in England, which we have undertaken.
4. The trends in liothyronine prescribing from the start of the NHS England Medicines Value Programme till August 2020.
5. A list of CCGs (in Appendix 3) where patients have directly reported to The Thyroid Trust that they are experiencing issues with accessing liothyronine, when they believe they are entitled to it under national guidelines.

CCG Prescribing status review and basis of the preparation of this data

The liothyronine policy status was obtained by a volunteer searching on websites for the formulary and policies of each CCG. The prescribing status of the CCGs have not been confirmed in writing with the CCGs. There are limitations in the collation of data. The data may not be fully up to date because not all formularies were easily identifiable or available to public access. Status may have changed since the policy was last reviewed in February 2021.

The number of CCG websites that were reviewed were 186.

The names of the CCGs were obtained from the NHS Clinical Commissioners' webpage in March 2020.

The CCG data for the prescribing of liothyronine was obtained from the Open Prescribing website. This website provided prescribing information for 136 CCGs.

This data is for England only.

The list of CCGs in Appendix 3 is taken from patient reports submitted directly to The Thyroid Trust, where patients submitted the first part of their postcode and volunteers matched this information with the relevant CCG. This data includes health authorities in Scotland.

Summary of findings

The majority (52%) of CCGs have explicitly not adopted RMOG guidance, or can be shown to not be consistently following national guidance and good practice on the prescribing of liothyronine.

- Only 24 of 186 (13%) CCG policies found and reviewed had adopted the Regional Medicines Optimisation Committee prescribing guidance for liothyronine, in full.
- Only 55 of the 186 (30%) CCG policies found and reviewed, including the above, had policies that seem to be in line with national guidance.
- A majority, 97 (52%) of CCG policies reviewed were not in line with national guidance.

- The remaining 34 (31%) CCG websites or formularies did not include sufficient information on the prescribing, or information was not found.
- Where CCG policy is not in line with national guidance, the main reasons are:
 - 16 (9%) of CCGs have a 'do not prescribe' or not on formulary policy on liothyronine.
 - 20 (11%) of CCGs have a policy that only permits prescribing in extreme circumstances, such as in the event of the patient going into a coma, or in hospital only.
 - 46 (25%) of CCGs' prescribing is only in secondary care and the patient will not be treated locally by their Primary Care GP but is expected to continue to get their ongoing prescriptions from Secondary Care. This is a costly approach to prescribing and dispensing and is clearly impractical for a medicine likely to be needed for life and for this reason this is explicitly against national guidance).
- There was a decrease in prescribing from the start of the NHS England consultation in July 2017 until December 2019 when the NICE guidance was released. The decrease was 28% or 1,596 fewer items prescribed (period on period comparison).
- There has been an increase of 4% in items prescribed per month between December 2019 and August 2020. This is mainly due to an increase of 169 items in those CCGs that have adopted RMOC or implemented a guideline that is in line with national guidance.
- Only one CCG, Norfolk and Waveney, has published an approved pathway for prescribing liothyronine. (5)

Recommendations

The RMOG liothyronine prescribing guidance is adopted by all CCGs who have not yet brought their local policy in line with the national guidance.

The Norfolk and Waveney pathway (4) which has been approved by the appropriate CCG policy governance and correctly adopts NICE, NHS England and RMOG guidance, is adopted by all CCGs who do not have policies that are consistent with national guidance.

These recommendations offer a cost effective and expedient way to ensure national guidance is adopted by all CCGs and that patients who require liothyronine are treated fairly and consistently across the country and will no longer have to resort to sourcing their medicine through other means or to being made unwell if they are unable to get it at all.

Additionally we recommend that the Health Service Medical Supplies (Costs) Act 2017 is enacted to address the cost issue, so that the NHS can start to pay a price for liothyronine which is more in line with what other health services in other countries are paying. It is clear to us that if the price issue were resolved the issues of CCGs withholding treatment would disappear and many more thyroid patients, who do not thrive on levothyroxine, would be able to access the treatment they need to be well, without having to go through tortuous battles with their healthcare providers.

Appendix 1/ List of the problematic CCGs, categorised by issue, A-H

[replace the multiple lists below - inserting table showing the below data in one list, with columns for each category]

Category A

The issue with CCGs we have classified Category A is that published information on their position states that liothyronine is either not on their formulary at all, or is listed as “do not prescribe”

Basildon and Brentwood CCG

Bassetlaw CCG

Brighton & Hove CCG

Camden CCG

Castle Point and Rochford CCG

Chorley and South Ribble CCG

Corby CCG

Mid Essex CCG

Milton Keynes CCG

Shropshire CCG

South Cheshire CCG

Southend CCG

Telford and Wrekin CCG

Thurrock CCG

Waltham Forest CCG

West Suffolk

Category B

The issue with CCGs we have classified as Category B is that published information on their position is that liothyronine can only be prescribed in hospital and/ or in unreasonably limited circumstances, which do not include treatment for hypothyroidism where levothyroxine is not suitable, such as the patient falling into a coma.

Bedfordshire CCG *

Blackburn with Darwen CCG

Buckinghamshire CCG

City and Hackney CCG

Coastal West Sussex CCG

East Lancashire CCG

Fylde and Wyre CCG

Gloucestershire CCG

Greater Preston CCG

High Weald Lewes Havens CCG

Mansfield and Ashfield CCG

Morecambe Bay CCG *

Newark and Sherwood CCG

Nottingham City CCG

Nottingham North and East CCG

Nottingham West CCG

Rushcliffe CCG

Tameside and Glossop CCG

Warwickshire North CCG

Wolverhampton CCG

Category C

The issue with CCGs we have classified as Category C is that published information on their position is that liothyronine can only ever be prescribed in secondary care which is unreasonable for a medicine many patients will be on for life and national guidance says should be prescribed in primary care after initiation and supervision by a specialist. Secondary care practitioners are a scarce resource in the NHS and it makes no sense for them to have to physically prescribe medicine on an ongoing basis, likewise it is very inconvenient for patients to have to go to secondary care for their ongoing prescriptions, as opposed to their GP, once they are stable and well.

Barnsley CCG

Birmingham and Solihull CCG

Bolton CCG

Bury CCG

Cambridgeshire And Peterborough CCG

Coventry and Rugby CCG

Dorset CCG

Dudley CCG

East and North Hertfordshire CCG

East Berkshire CCG

East Surrey CCG *

Halton CCG

Hambleton, Richmondshire and Whitby CCG

Herefordshire CCG

Herts Valleys CCG

Heywood, Middleton and Rochdale CCG

Ipswich And East Suffolk CCG

Kingston CCG

Knowsley CCG

Liverpool CCG

Luton CCG

Manchester CCG

North East Hampshire and Farnham CCG

North East Lincolnshire CCG

North Hampshire CCG

North Lincolnshire CCG *

Oldham CCG

Redditch and Bromsgrove CCG

Richmond CCG

Salford CCG

Sandwell and West Birmingham CCG

South Lincolnshire CCG

South Sefton CCG *

South Warwickshire CCG

South West Lincolnshire CCG

Southport and Formby CCG *

St Helens CCG

Stockport CCG

Sutton CCG

Trafford CCG

Vale Royal CCG

Warrington CCG

West Lancashire CCG

Wigan Borough CCG

Wirral CCG

Wyre Forest CCG

Category D

The issue with CCGs we have classified as Category D is that their published information on their position diverges from national guidance because it states that patients should be switched from treatment with liothyronine, regardless of clinical appropriateness.

Bexley CCG

Bromley CCG

Greenwich CCG liothyronine, regardless of clinical appropriateness

Lambeth CCG

Lewisham CCG

Merton CCG

Southwark CCG

Wandsworth CCG

Category E

The issue with CCGs we have classified as Category E is that their published information on their position diverges from national guidance because it states that liothyronine can only be prescribed following an IFR process - which NHS England have told us is not suitable for treatment known to be required by a cohort of patients.

Derby and Derbyshire CCG

Southampton City CCG

West Hampshire CCG

Category F

The issue with the CCG we have classified as Category F is that this CCG states that a trial off of liothyronine is required in order to confirm clinical need (the British Thyroid Association guidance is clear that if a patient is stable and well on liothyronine their treatment should not be disrupted as this can cause harm and take a long time to be put right). In addition this CCG puts a limit on the maximum dose that can be prescribed, which is entirely

unreasonable as different patients will need different amounts and clinicians should not be dictated to on the dose they can prescribe.

Devon CCG

Category G

The issue with the CCGs we have classified as category G is that their positions in relation to liothyronine are unclear, from what we could glean from published information.

Brent CCG

Cannock Chase CCG

Dartford Gravesham and Swanley CCG

Doncaster CCG

Ealing CCG

East Riding of Yorkshire CCG

East Staffordshire CCG

Eastern Cheshire CCG

Fareham and Gosport CCG

Hammersmith and Fulham CCG

Harrow CCG

Hillingdon CCG

Hounslow CCG

Kernow CCG

Lincolnshire East CCG

Lincolnshire West CCG

Rotherham CCG

Somerset CCG *

South East Staffordshire and Seisdon Peninsular CCG

South Eastern Hampshire CCG

South Worcestershire CCG

Stafford And Surrounds CCG

Stoke on Trent CCG

West Essex

West Kent CCG

West London CCG

Category H

The issue with the CCGs we have classified as Category H is that their positions in relation to liothyronine could not be found.

Barking and Dagenham CCG

Croydon CCG

Havering CCG

Horsham And Mid Sussex CCG

Nene CCG

Redbridge CCG

South Kent Coast CCG

South Tyneside CCG

Thanet CCG

West Cheshire CCG

Appendix 2/ CCGs policy review summary - all CCGs in England

The table includes links to each document reviewed and the comments field includes some aspects that were highlighted by our volunteer researcher.

CCG	Prescribing Status Mar 20	Date	Comments	Source
Airedale, Wharfedale and Craven CCG	RMOC			https://www.wyhpartnership.co.uk/application/files/4615/5120/1588/20_19_WYHJC_Planned_Care_-_Liothyronine_1.2_FINAL.pdf
Ashford CCG	AMBER	2017	Out of date - refers to the 2017 consultation	http://bswformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Barking and Dagenham CCG	NOT FOUND			
Barnet CCG	Do not prescribe		Do not initiate in both primary and secondary. Secondary care patients to be switched where clinically appropriate	https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/6_Liothyronine_position_statement.pdf
Barnsley CCG	RED		The RMOC Prescribing of Liothyronine Guidance was received and noted. It was agreed that liothyronine would remain classified red in Barnsley	https://www.barnsleyccg.nhs.uk/CCG%20Downloads/Members/Medicines%20management/Area%20prescribing%20committee/201908%20-%20APC%20Minutes%20Ratified%20-%20August%202019.pdf

Basildon and Brentwood CCG	Non formulary	2016	Just mentions levothyroxine. RCP 2011 referenced	https://basildonandbrentwoodccg.nhs.uk/about-us/publications/key-documents/medicines-management/formulary-guidelines-and-shared-care-paths/06-endocrine-system/1876-chapter-6-endocrine-system/file https://www.thurrockccg.nhs.uk/about-us/document-library/medicines-management/position-statements/4103-liothyronine-or-unlicensed-dried-thyroid-hormone-extracts/file
Bassetlaw CCG	Non formulary	Feb-16	No mention liothyronine other than injection	https://oesn11hpbml2xaq003wx02ib-wpengine.netdna-ssl.com/wp-content/uploads/2018/05/Section-6.2.pdf
Bath and North East Somerset CCG	AMBER		<p>Liothyronine is non formulary for monotherapy</p> <p>Please note this is a high cost medicine</p> <p>The British Thyroid Association (BTA) advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction.</p> <p>In these circumstances, where levothyroxine has failed and in line with BTA guidance,</p>	http://bswformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

			<p>endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.</p> <p>Liothyronine is used for patients with thyroid cancer, in preparation for radioiodine ablation, iodine scanning, or stimulated thyroglobulin test. In these situations it is appropriate for patients to obtain their prescriptions from the centre undertaking the treatment and not be routinely obtained from primary care prescribers.</p>	
Bedfordshire CCG *	Restricted	Jun-18		http://www.bedsformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search
Berkshire West CCG	Restricted	May-19	Own guidelines / shared care	http://westberks.formulary.co.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

Bexley CCG	GREY		Put T3 patients on T4 No new patients	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine
Birmingham and Solihull CCG	RED			http://www.birminghamandsurroundsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Blackburn with Darwen CCG	BLACK			http://www.elmmb.nhs.uk/specialist-formulary/black-traffic-light-drugs-not-recommended-for-use/
Blackpool CCG	RED			https://www.fyldecoastccgs.nhs.uk/?wpfb_dl=1170&no_preview=1
Bolton CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Bradford City CCG	RMOC	May-19		https://www.swyapc.org/wp-content/uploads/2019/06/FINAL-liothyronine-SCG-May-19.pdf
Bradford Districts CCG	RMOC	May-19		https://www.swyapc.org/wp-content/uploads/2019/06/FINAL-liothyronine-SCG-May-19.pdf
Brent CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Brighton & Hove CCG	Do not prescribe		Statement that they differ from NHSE	https://www.gp.brightonandhoveccg.nhs.uk/joint-formulary

Bristol, North Somerset and South Gloucestershire CCG	AMBER			http://bswformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Bromley CCG	GREY		Put T3 patients on T4 No new patients	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine
Buckinghamshire CCG	Restricted		Only if levo intolerance	http://www.bucksformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4852#4852
Bury CCG	Green			http://gmmmg.nhs.uk/docs/formulary/ch/Ch6-complete.pdf
Calderdale CCG	RMOC			https://www.wyhpartnership.co.uk/application/files/4615/5120/1588/20_19_WYHJC_Planned_Care_-_Liothyronine_1.2_FINAL.pdf
Cambridgeshire And Peterborough CCG	Restricted			http://www.cambridgeshireandpeterboroughformulary.nhs.uk/searchresults.asp?SearchVar=Liothyronine+&Submit2=Search
Camden CCG	Restricted		https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/6_Liothyronine_position_statement.pdf?UNLID=336361778202036183110	http://www.ncl-jointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

Cannock Chase CCG	AMBER			http://www.southstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Canterbury and Coastal CCG	RMOC			http://www.ekhuffformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Castle Point and Rochford CCG	Do not prescribe			https://southendccg.nhs.uk/your-health-services/healthcare-professionals/medicines-management/bnf-chapter-6-endocrine/3283-1-endocrine-formulary/file
Central London (Westminster) CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Chorley and South Ribble CCG	RMOC			https://www.lancsmmg.nhs.uk/media/1273/rmoc-liothyronine-guidance-v26-final-1.pdf

City and Hackney CCG	AMBER	<p>Liothyronine prescribing Use restricted to:</p> <ol style="list-style-type: none">1. Levothyroxine failure2. Thyroid cancer, in preparation for radioiodine ablation, iodine scanning, or stimulated thyroglobulin test <p>Only to be initiated in secondary/ tertiary care</p> <p>Refer patient to endocrinology team for review. If the patient is to continue with treatment after review or treatment is initiated by an endocrinologist for restricted indications then the rationale for this should be clearly documented in the clinic letter. Prescribing can be continued in primary care provided that there is a clear rationale for prescribing (i.e. as per the list of restricted indications). The rationale is</p>	<p>https://www.formularycomplete.com/report/public/CHCCG%20&%20HUHFT%20Joint%20Formulary/95154</p>
----------------------	-------	---	--

			should be clearly documented in the patient's EMIS record.	
Coastal West Sussex CCG	BLUE		Specialist only	http://www.coastalwestsussexformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Corby CCG	Do not prescribe		R R non formulary	http://www.northamptonformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Coventry and Rugby CCG	SO			http://www.covwarkformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804

Crawley CCG	RED	<p>Following thyroidectomy where a patient requires liothyronine until radioactive iodine is no longer indicated (PCN 186-2016)</p> <p>Treatment of coma of myxoedema (APC 408-2019)</p> <p>Severe chronic thyroid deficiency and hypothyroid states occurring in the treatment of thyrotoxicosis (APC 409-2019)</p> <p>Treatment of resistant depression (APC 410-2019)</p> <p>Liothyronine monotherapy in oncology - thyroid and parathyroid disease (APC 421-2019)</p> <p>Liothyronine sodium (monotherapy) - Hypothyroidism in adults with an intolerance to levothyroxine.</p> <p>Please note the Crawley, Horsham and Mid-Sussex CCG decision is RED and differs from</p>	<p>http://www.chmsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=5317#5317</p>
-------------	-----	---	--

			<p>the Surrey APC decision of AMBER. (APC 412-2019)</p> <p>Liothyronine sodium (combination) - Hypothyroidism in adults with an inadequate response to levothyroxine.</p> <p>Please note the Crawley, Horsham and Mid-Sussex CCG decision is RED and differs from the Surrey APC decision of AMBER. (APC 411-2019)</p>	
Croydon CCG				
Darlington CCG	RMOC			https://medicines.necsu.nhs.uk/guidelines/durham-darlington/
Dartford Gravesham and Swanley CCG	AMBER			http://www.dgsdvhformulary.nhs.uk/therapeutic-sections/6-endocrine-system/62-thyroid-and-antithyroid-drugs/621-thyroid-hormones/
Derby and Derbyshire CCG *	BLACK			http://www.derbyshiremedicinesmanagement.nhs.uk/medicines-management/search?search=liothyronine
Devon CCG *	AMBER		<p>Liothyronine may be suitable for a small number of patients whose symptoms have not resolved despite optimal treatment with levothyroxine.</p> <p>Liothyronine is restricted to a</p>	https://southwest.devonformularyguidance.nhs.uk/formulary/chapters/6.-endocrine/6.2-thyroid-and-antithyroid-drugs/6-2-1-thyroid-hormones-1

			maximum dose of 10 micrograms daily as dual therapy with levothyroxine initiated by an endocrinologist. Liothyronine monotherapy is not supported	
Doncaster CCG	AMBER			http://medicinesmanagement.doncasterccg.nhs.uk/tls/liothyronine-sodium-tabs/
Dorset CCG	Restricted		Shared care	http://www.dorsetformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Dudley CCG	Shared Care Only			https://www.dudleyformulary.nhs.uk/formulary/201/621-thyroid-hormones
Durham Dales, Easington and Sedgefield CCG	RMOC			https://medicines.necsu.nhs.uk/guidelines/durham-darlington/
Ealing CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
East and North Hertfordshire CCG	AMBER		Patients who are already receiving liothyronine on prescription from their GP, prescribing to remain in primary care, providing a trial of T4 for 6 months or longer has been undertaken in the past	http://www.westhertsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

East Berkshire CCG	RED			http://www.frimleyhealthformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
East Lancashire CCG	BLACK			http://www.elmmb.nhs.uk/elmmb-formulary/joint-medicines-formulary/6/
East Leicestershire and Rutland CCG	Restricted			http://leicestershire.formulary.co.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=2803#2803
East Riding of Yorkshire CCG	RED			https://www.hey.nhs.uk/wp/wp-content/uploads/2016/11/liothyronine.pdf
East Staffordshire CCG	AMBER			http://www.southstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
East Surrey CCG *	RED			http://www.frimleyhealthformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Eastbourne, Hailsham and Seaford CCG	AMBER		Shared care	http://www.eastsussexformulary.co.uk/therapeutic-sections/6-endocrine-system/62-thyroid-and-antithyroid-drugs/621-thyroid-hormones/
Eastern Cheshire CCG	Do not prescribe			http://www.centralandeasterncheshiremmt.nhs.uk/formulary/chapters/191
Enfield CCG	restricted		Individuals currently prescribed liothyronine should	http://www.ncl-jointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSection

			be reviewed by a consultant NHS endocrinologist with consideration given to switching to levothyroxine where clinically appropriate.	Ref=06.02.01&SubSectionID=A100&drugmatch=446#446
Fareham and Gosport CCG	restricted		To be initiated by NHS secondary care only for approved indications	http://www.portsmouthareaformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Fylde and Wyre CCG	RED			https://www.fyldecoastccgs.nhs.uk/?wpfb_dl=1170&no_preview=1
Gloucestershire CCG	restricted		Liothyronine Injection: Hypothyroid coma / rapid response desired (Seek specialist advice)	https://www.gloshospitals.nhs.uk/gps/gloucestershire-joint-formulary/endocrine-system/
Great Yarmouth and Waveney CCG	Green		Liothyronine (T3) for RESTRICTED use for patients on levothyroxine for hypothyroidism who continue to suffer with symptoms despite adequate biochemical correction: - for new patients, NHS Consultant to prescribe for 3 months, then to the GP.	https://www.knowledgeanglia.nhs.uk/LinkClick.aspx?fileticket=rdPU5BVn8J0%3d&portalid=1

			- for existing patients, NHS Consultant to review, then, if appropriate, to the GP.	
Greater Huddersfield CCG	RED			https://www.swyapc.org/search-by-drug-classification/
Greater Preston CCG	RMOC			https://www.lancsmmg.nhs.uk/media/1273/rmoc-liothyronine-guidance-v26-final-1.pdf
Greenwich CCG	GREY	Jan-20	Put T3 patients on T4 No new patients	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine
Guildford and Waverley CCG	restricted		Hypothyroidism for patients with an intolerant to levothyroxine (T4) or Amber Rare patients who remain symptomatic despite optimal biochemical replacement with levothyroxine. This treatment must be initiated and monitored by an NHS Endocrinologist. (APC411-2019)	http://www.guildfordandwaverleyformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
Halton CCG	RED			http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSecti

				onRef=06.02.01&SubSectionID=A100&drugmatc h=446#446
Hambleton, Richmondshire and Whitby CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Hammersmith and Fulham CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Haringey CCG	AmBER		<p>Liothyronine prescribing Use restricted to:</p> <ol style="list-style-type: none"> 1. Levothyroxine failure 2. Thyroid cancer, in preparation for radioiodine ablation, iodine scanning, or stimulated thyroglobulin test 	https://www.formularycomplete.com/report/public/CHCCG%20&%20HUHFT%20Joint%20Formulary/95154
Harrogate and Rural District CCG	Restricted			<a href="http://www.harrogateformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatc
h=447#447">http://www.harrogateformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatc h=447#447
Harrow CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Hartlepool and Stockton on tees CCG	RMOC			https://medicines.necsu.nhs.uk/guidelines/durham-darlington/
Hastings and Rother CCG	AMBER		Shared care	http://www.eastsussexformulary.co.uk/therapeutic-sections/6-endocrine-system/62-thyroid-and-antithyroid-drugs/621-thyroid-hormones/
Havering CCG	Not found			

Herefordshire CCG	RMOC			https://www.herefordshireccg.nhs.uk/search?q=Liothyronine+&submit=
Herts Valleys CCG	RED		Hospital clinicians only	https://hertsvalleysccg.nhs.uk/application/files/1515/3633/4214/Liothyronine_for_hypothyroidism_decision_document_032018_HMMC.pdf
Heywood, Middleton and Rochdale CCG	GREY	Feb-19		http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
High Weald Lewes Havens CCG	Do not prescribe		Statement that they do not apply NHSE guidance	https://www.gp.brightonandhoveccg.nhs.uk/joint-formulary
Hillingdon CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Horsham And Mid Sussex CCG	RED			http://www.chmsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=5317#5317
Hounslow CCG	RMOC			https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf
Hull CCG	RED			https://www.hey.nhs.uk/wp/wp-content/uploads/2016/11/liothyronine.pdf
Ipswich And East Suffolk CCG	Restricted			http://www.ipswichandeastsuffolkformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
Isle of Wight CCG	YELLOW		Drugs that may be continued in primary care following initiation and stabilisation in secondary/tertiary care	http://www.iowformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804

Islington CCG	Do not prescribe			https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/6_Liothyronine_position_statement.pdf
Kernow CCG	AMBER		Specialist Initiated Drugs	https://www.eclipsesolutions.org/cornwall/?run=yes&search=Liothyronine%20&bnf=False&notes=False
Kingston CCG	Restricted		Endo only	https://www.kingstonformulary.nhs.uk/formulary/201/621-thyroid-hormones
Knowsley CCG	RED			http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Lambeth CCG	GREY		Put T3 patients on T4 No new patients	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine
Leeds CCG	Restricted			http://www.leedsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#447
Leicester City CCG	RMOC			http://leicestershire.formulary.co.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=2803#2803

Lewisham CCG	GREY		Put T3 patients on T4 No new patients	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine
Lincolnshire East CCG	Amber			http://www.lincolnshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#447
Lincolnshire West CCG	Amber			http://www.lincolnshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#448
Liverpool CCG	RED			http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Luton CCG	Restricted			http://www.bedsformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search
Manchester CCG	GREY	Feb-19		http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Mansfield and Ashfield CCG	Restricted			http://www.nottinghamshireformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search

Medway CCG	RED		cancer patients only	http://www.medwayswaleformulary.co.uk/therapeutic-sections/6-endocrine-system/69-thyroid-disorders/692-hypothyroidism/
Merton CCG	RED	Mar-19	Temporary thyroid replacement therapy after thyroidectomy and prior to radioiodine therapy. Hospital only prescribing	http://www.selondonjointmedicinesformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100#6090
Mid Essex CCG	Do not prescribe		Levothyroxine alone is the treatment of choice for hypothyroidism.	https://midessexccg.nhs.uk/search?q=Liothyronine+
Milton Keynes CCG				
Morecambe Bay CCG *	BLACK		Black new patients. On the recommendation of a Consultant Endocrinologist for patients who have already been initiated on it and cannot be switched due to adverse reactions. After such a review by a consultant endocrinologist liothyronine may be continued as AMBER in primary care	http://www.morecambebayformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100
Nene CCG				

Newark and Sherwood CCG	Restricted			http://www.nottinghamshireformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search
Newcastle and Gateshead CCG	GREEN			http://northoftyneandgatesheadformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Newham CCG	Do not prescribe	Jul-18	Prescribers in primary or secondary care should not initiate liothyronine for any new patient.	https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/6_Liothyronine_position_statement.pdf?UNLID=510097285202037171018
North Cumbria CCG	GREEN			http://northoftyneandgatesheadformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
North Durham CCG	RMOC			https://medicines.necsu.nhs.uk/guidelines/durham-darlington/
North East Essex CCG	Restricted			http://www.ipswichandeastsuffolkformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
North East Hampshire and Farnham CCG	RED		Hospital clinicians only	http://www.frimleyhealthformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

North East Lincolnshire CCG	RED			http://www.apcnlgformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100
North Hampshire CCG	RED			http://www.frimleyhealthformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
North Kirklees CCG	RMOC	Apr-19	Out of date :Liothyronine (T3) has had a significant increase in price over the last few years. It is only available from one manufacturer, and has been subject to interruptions in supply availability in recent years	https://www.swyapc.org/wp-content/uploads/2019/05/Commissioning-Statement-liothyronine-FINAL-v1-Apr-19.pdf
North Lincolnshire CCG *	RED			http://www.apcnlgformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100
North Norfolk CCG				
North Staffordshire CCG	Amber			http://www.northstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
North Tyneside CCG	GREEN			http://northoftyneandgatesheadformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

North West Surrey CCG	AMBER		red thyroid cancer / mono	https://www.surreyandsussex.nhs.uk/trust-formulary/bnf-chapter-6/
Northumberland CCG	GREEN			http://northoftyneandgatesheadformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Norwich CCG				
Nottingham City CCG	Restricted		<p>Expensive (£376 per 20microgram dose). For hypothyroid crisis on request of consultant endocrinologist. Levothyroxine has very long half life (~7 days) so temporary IV replacement if NBM is not needed.</p> <p>SFH only: To be used request of consultant endocrinologist, and only on ICCU.</p> <p>NUH only: For use for temporary replacement of levothyroxine, when scheduled to have nuclear medicine scan of the thyroid gland and it is not possible to come off oral levothyroxine.</p>	http://www.nottinghamshireformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search

Nottingham North and East CCG	Restricted	<p>Expensive (£376 per 20microgram dose). For hypothyroid crisis on request of consultant endocrinologist. Levothyroxine has very long half life (~7 days) so temporary IV replacement if NBM is not needed.</p> <p>SFH only: To be used request of consultant endocrinologist, and only on ICCU.</p> <p>NUH only: For use for temporary replacement of levothyroxine, when scheduled to have nuclear medicine scan of the thyroid gland and it is not possible to come off oral levothyroxine.</p>	http://www.nottinghamshireformulary.nhs.uk/search/results.asp?SearchVar=liothyronine&Submit2=Search
Nottingham West CCG	Restricted	<p>Expensive (£376 per 20microgram dose). For hypothyroid crisis on request of consultant endocrinologist. Levothyroxine has very long half life (~7 days) so temporary IV replacement if NBM is not needed.</p>	http://www.nottinghamshireformulary.nhs.uk/search/results.asp?SearchVar=liothyronine&Submit2=Search

			<p>SFH only: To be used request of consultant endocrinologist, and only on ICCU.</p> <p>NUH only: For use for temporary replacement of levothyroxine, when scheduled to have nuclear medicine scan of the thyroid gland and it is not possible to come off oral levothyroxine.</p>	
Oldham CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Oxfordshire CCG	RMOC			http://www.oxfordshireformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
Portsmouth CCG	Restricted		Amber Initiated: first prescription from specialist, on going supplies from primary care (or when stabilised on therapy).	http://www.portsmouthareaformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Redbridge CCG				
Redditch and Bromsgrove CCG	RED		Consultation	http://www.worcsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#447

Richmond CCG	Restricted			https://www.kingstonformulary.nhs.uk/formulary/201/621-thyroid-hormones
Rotherham CCG	GREEN			http://www.therotherhamftformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100&FC=1
Rushcliffe CCG	Restricted			http://www.nottinghamshireformulary.nhs.uk/searchresults.asp?SearchVar=liothyronine&Submit2=Search
Salford CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Sandwell and West Birmingham CCG	RED		Consultation	http://www.sandwellandwestbhamccgformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Scarborough and Ryedale CCG	AMBER			http://www.yorkandscarboroughformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4028#4028
Sheffield CCG	BLACK			http://www.sheffieldteachinghospitalsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=3308#3308
Shropshire CCG	BLACK			http://www.shropshireandtelfordformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

Somerset CCG *	RED		Liothyronine (T3) is classified as not recommended for primary care initiation and considered red when consultant requested	http://formulary.somersetccg.nhs.uk/?page_id=771
South Cheshire CCG	Do not prescribe			http://www.centralandeasterncheshiremnt.nhs.uk/formulary/chapters/191
South East Staffordshire and Seisdon Peninsular CCG	AMBER			http://www.southstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
South Eastern Hampshire CCG	Restricted		To be initiated by NHS secondary care only for approved indications	http://www.portsmouthareaformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
South Kent Coast CCG				
South Lincolnshire CCG	RED			http://www.apcnlgformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100
South Norfolk CCG	RED			https://www.knowledgeanglia.nhs.uk/kms/LinkClick.aspx?fileticket=QaUeiUvL_pl%3d&portalid=1
South Sefton CCG *	RED			http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
South Tees CCG	RMOC			http://joint-formulary.tees.nhs.uk/6-endocrine-system/?rand=637179707603042455#liothyronine-8063

South Tyneside CCG	NOT FOUND			
South Warwickshire CCG	SO			http://www.covwarkformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
South West Lincolnshire CCG	RED			http://www.apcnlgformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100
South Worcestershire CCG	Do not prescribe	2017	NHS 2017 consultatin - Liothyronine has a similar action to levothyroxine but is more rapidly metabolised and has a more rapid effect; 20–25 micrograms is equivalent to 100 micrograms of levothyroxine. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment. It may be used in severe hypothyroid states when a rapid response is desired.	http://www.worcsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#447
Southampton City CCG	RMOC			http://www.southamptonformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804

Southend CCG	Do not prescribe		No mention of liothyronine as alternative to levothyroxine	https://southendccg.nhs.uk/your-health-services/healthcare-professionals/medicines-management/bnf-chapter-6-endocrine/3283-1-endocrine-formulary/file
Southport and Formby CCG *	RED		Existing stable patients in primary care may continue to be prescribed liothyronine by the GP where they are satisfied the patient is benefiting specifically from the use of liothyronine.	http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Southwark CCG	NICE - do not prescribe		<p>The SEL APC has considered guidance from the national Regional Medicines Optimisation Committee (RMOC) in developing this position statement and NICE guidance.</p> <p>Routine prescribing of liothyronine (monotherapy or in combination with levothyroxine) for hypothyroidism is not recommended in SEL.</p> <p>NICE has published updated guidance for the assessment</p>	https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/APC%20Position%20Statement%20PS-021%20Liothyronine%20FINAL%20Grey%20Feb%202020.pdf#search=Liothyronine

			and management of thyroid disease [NG145]. In the guidance for managing primary hypothyroidism it is highlighted not to routinely offer liothyronine, either alone or in combination with levothyroxine. This is because there is not enough evidence that it offers benefits over levothyroxine monotherapy and its long-term adverse effects are uncertain.	
St Helens CCG	RED		Existing stable patients in primary care may continue to be prescribed liothyronine by the GP where they are satisfied the patient is benefiting specifically from the use of liothyronine.	http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Stafford And Surrounds CCG	AMBER	2017	Only to be prescribed for clinically appropriate patients after specialist initiation when Levothyroxine not clinically tolerated.	http://www.southstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446

			NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). Although this drug is clinically effective, there are more cost-effective products available.	
Stockport CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Stoke on Trent CCG	Amber	2017	<p>Only to be prescribed for clinically appropriate patients after specialist initiation when Levothyroxine not clinically tolerated.</p> <p>NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). Although this drug is clinically effective, there are more cost-effective products available.</p>	http://www.northstaffordshirejointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Sunderland CCG	GREEN			http://www.formulary.sunderlandccg.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&Sub

				SectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Surrey Downs CCG *	AMBER		red thyroid cancer / mono	https://www.surreyandsussex.nhs.uk/trust-formulary/bnf-chapter-6/
Surrey Heath CCG	AMBER		red thyroid cancer / mono	https://www.surreyandsussex.nhs.uk/trust-formulary/bnf-chapter-6/
Sutton CCG	RED	Mar-19	Temporary thyroid replacement therapy after thyroidectomy and prior to radioiodine therapy. Hospital only prescribing	http://www.selondonjointmedicinesformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100#6090
Swale CCG	RED		cancer patients only	http://www.medwayswaleformulary.co.uk/therapeutic-sections/6-endocrine-system/69-thyroid-disorders/692-hypothyroidism/
Swindon CCG	AMBER			http://bswformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Tameside and Glossop CCG	Restricted			http://www.tamesideformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06&SubSectionID=A100&FC=1
Telford and Wrekin CCG	BLACK		Non formulary. Consultation 2017	http://www.shropshireandtelfordformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Thanet CCG				

Thurrock CCG	Do not prescribe		Only levothyroxine	https://www.thurrockccg.nhs.uk/about-us/document-library/medicines-management/formulary-and-prescribing-guidelines/1472-endocrine-system-formulary/file
Tower Hamlets CCG	Do not prescribe	Jul-18	Prescribers in primary or secondary care should not initiate liothyronine for any new patient.	https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/6_Liothyronine_position_statement.pdf?UNLID=510097285202037171018
Trafford CCG	GREY			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf
Vale of York CCG	AMBER		Requires initiation or recommendation by a specified member of the Hospital Specialist Team. Suitable for continuation by a GP, with appropriate supporting documents. No written shared care agreement necessary	http://www.yorkandscarboroughformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4028#4028
Vale Royal CCG	Do not prescribe	Mar-18	NHS England has identified this product as an item that should not be routinely prescribed in primary care. The treatment should only be started / continued in exceptional circumstances where: symptoms persist despite	http://www.centralandeasterncheshiremmt.nhs.uk/formulary/chapters/191

			biochemical correction of thyroid function tests with levothyroxine; and following a trial of at least 3 months under the supervision of an NHS Endocrinologist; and where the NHS Endocrinologist has agreed there is an ongoing need for liothyronine [Agreed at Area Prescribing Group on 13 Mar 2018]	
Wakefield CCG	RED			https://www.swyapc.org/search-by-drug-classification/
Walsall CCG	RMOC		Shared care	https://walsallccg.nhs.uk/wp-content/uploads/Liothyronine-ESCA-Approved-Exp-Oct-2021.pdf
Waltham Forest CCG	SO		Dated 2016	https://www.walthamforestccg.nhs.uk/downloads/ourwork/Medicines-optimisation/Medicines-guidelines/Endocrine/liothyronine.pdf
Wandsworth CCG	RED	Mar-19	Temporary thyroid replacement therapy after thyroidectomy and prior to radioiodine therapy. Hospital only prescribing	http://www.selondonjointmedicinesformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100#6090
Warrington CCG	RED		Existing stable patients in primary care may continue to	http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSecti

			be prescribed liothyronine by the GP where they are satisfied the patient is benefiting specifically from the use of liothyronine.	onRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Warwickshire North CCG	SO	Jun-19	The Area Prescribing Committee recommends that liothyronine is prescribed only by the specialist. The committee recognises that some patients have been established on the product for a considerable time and this may be difficult to change. Hence there will be some legacy prescribing in primary care. However all those newly started on liothyronine should be under specialist supervision and should be changed to levothyroxine for routine therapy when primary care prescription is requested.	http://www.covwarkformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionID=A100&drugmatch=4804#4804
West Cheshire CCG	NOT FOUND			

West Essex	PRESQIPP	Feb-16	Review all patients taking liothyronine (alone or in combination with levothyroxine) for suitability for switching to levothyroxine. Switch all suitable patients to levothyroxine. For patients under the care of a relevant specialist, involve them in the decision to switch to levothyroxine.	https://westessexccg.nhs.uk/your-health/medicines-optimisation-and-pharmacy/clinical-guidelines-and-prescribing-formularies/06-endocrine-system/83-liothyronine/file
West Hampshire CCG	RMOC			http://www.southamptonformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=4804#4804
West Kent CCG	AMBER		DO NOT PRESCRIBE ROUTINELY OR INITIATE IN PRIMARY CARE. TO BE USED IN EXCEPTIONAL CIRCUMSTANCES ONLY ON SPECIALIST ADVICE	http://www.formularywkccgmtw.co.uk/therapeutic-sections/endocrine-system/thyroid-disorders/hypothyroidism/

West Lancashire CCG	RED	May-1 6	<p>Liothyronine is NOT recommended for use by the NHS in Lancashire in the following setting:</p> <ul style="list-style-type: none"> • as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine. There is insufficient evidence to demonstrate efficacy in the above setting, availability of the drug is limited, adverse events are more prevalent than for levothyroxine monotherapy and there would be a considerable cost pressure to the health economy if prescribed for all patients with normal serum TSH levels and have persistent symptoms. 	https://www.lancsmmg.nhs.uk/medicines-library/liothyronine-1/
West Leicestershire CCG	RMOC		For patients who have had an inadequate response to thyroxine alone, in line with RMOC guidance, discontinuation if no improvement after 12 months.	http://leicestershire.formulary.co.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=2803#2803

West London CCG	RMO	Sep-19	<p>NHS England guidance https://www.england.nhs.uk/publication/items-which-should-not-be-routinely-prescribed-in-primary-care-guidance-for-ccgs/ Should not routinely be prescribed in primary care. Individuals prescribed liothyronine should be reviewed by a consultant NHS endocrinologist with consideration given to switching to levothyroxine where clinically appropriate. Should only be used in line with guidance from the Regional Medicines Optimisation Committee https://www.sps.nhs.uk/wp-content/uploads/2018/11/RMO-C-Liothyronine-Guidance-v2.0-final-1.pdf</p>	<p>https://www.hounslowccg.nhs.uk/media/137944/Formulary-Master-V34.pdf</p>
West Norfolk CCG	RED	Mar-18	Hospital only prescribing (Red)	<p>https://www.knowledgeanglia.nhs.uk/kms/LinkClick.aspx?fileticket=QaUeiUvL_pl%3d&portalid=1</p>

West Suffolk	Restricted	Feb-18	<p>The West Suffolk Clinical Commissioning Group (WSCCG) does not support the prescribing of liothyronine monotherapy or combination therapy or Armour® Thyroid in the long term treatment of hypothyroidism. Levothyroxine alone is the treatment of choice, supported by overwhelming evidence; it is a well-tolerated and effective treatment.</p>	<p>http://www.westsuffolkccg.nhs.uk/wp-content/uploads/2018/03/WSCCG-WSFT-Liothyronine-Prescribing-Policy-final-v2-Feb-2018.pdf</p>
Wigan Borough CCG	GREY	Feb-19	<p>GREY listing statement for liothyronine to be updated as follows: 'where levothyroxine has failed, endocrinologists treating patients under the NHS may recommend liothyronine in exceptional circumstances for individual patients and after a carefully audited trial of at least 3 months duration, in line with BTA guidance.</p>	<p>http://gmmmg.nhs.uk/docs/subgroups/sbgrp-fmesg/FMESG-Feb-2019-minutes-FINAL.pdf</p>

Wiltshire CCG	AMBER	Jan-19	<p>Shared care . The British Thyroid Association (BTA) advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction.</p> <p>In these circumstances, where levothyroxine has failed and in line with BTA guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.</p>	http://bswformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=446#446
Wirral CCG	RED		<p>Existing stable patients in primary care may continue to be prescribed liothyronine by the GP where they are satisfied the patient is benefiting specifically from the use of liothyronine</p>	http://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100

Wolverhampton CCG	Restricted		Severe hypothyroid state only. Prescribing initiated and regularly reviewed with regard to on-going clinical need by consultant NHS endocrinologist may be continued in primary care.	http://www.wolverhamptonformulary.nhs.uk/formulary/BNF/Section%206%20Endocrine/bnf6.asp#621
Wyre Forest CCG	Do not prescribe	2019	Refers to items that should not be routinely prescribed updated 2019	http://www.worcsformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.02.01&SubSectionID=A100&drugmatch=447#447

Appendix 3/ List of CCGs where The Thyroid Trust have received reports of difficulties, directly from individual patients.

Reports were submitted by individual patients via a form on The Thyroid Trust website between January 2020 and March 2021 and continue to be received. The below list relates to all reports downloaded up to 4/3/2021.

Details of each issue reported for each CCG are available, redacted of personal data.

The List of CCGs in England that patients have reported to The Thyroid Trust as not following national guidance on liothyronine prescribing is as follows (duplicates show multiple reports received).

NB: This list includes CCGs in Wales and Several NHS Board Areas in Scotland who also need to be investigated further.

Bath and North East Somerset, Swindon and Wiltshire CCG

Birmingham and Solihull CCG

Brighton & Hove

Bristol, North Somerset And South Gloucestershire CCG

Bristol, North Somerset and South Gloucestershire CCG

Buckinghamshire CCG

Cambridgeshire & Peterborough CCG

Cambridgeshire & Peterborough CCG

Cambridgeshire and Peterborough CCG

Derby and Derbyshire CCG

Devon CCG

Devon CCG

Dorset CCG

Dumbarton, Scotland.

West Dunbartonshire Community Health and Care Partnership

East and North Hertfordshire CCG

East Lancashire CCG
East Riding of Yorkshire CCG
East Sussex CCG
Edinburgh
Greater Preston CCG
Glasgow, Scotland
Havering CCG
Herefordshire & Worcestershire CCG
Herefordshire and Worcestershire CCG
Herts Valleys CCG
Herts Valleys CCG
Ipswich & East Suffolk CCG
Irvine, Ayrshire.
Mansfield & Ashfield CCG and Newark & Sherwood CCG
North Ayrshire Community Health Partnership
Jersey postcode
Kent & Medway CCG
Kent & Medway CCG
Kent & Medway CCG
Kernow CCG
Morecambe Bay CCG
NHS Bath and North East Somerset, Swindon and Wiltshire CCG
NHS Lothian
Norfolk and Waveney CCG
North Central London CCG
North Central London CCG
North Cumbria CCG
Northamptonshire CCG

Nottingham & Nottinghamshire CCG

Portsmouth CCG

Sheffield CCG

Shropshire CCG

Somerset CCG

Somerset CCG

Somerset CCG

Somerset CCG

Bath and North East Somerset, Swindon and Wiltshire CCG

South East London CCG

South East London CCG

South East London CCG

South Eastern Hampshire

South Sefton

South Sefton CCG

Southport & formby CCG

South Warwickshire CCG

South West London CCG

South West London CCG

South West London CCG

South West London CCG

Stafford and Surrounds CCG

Surrey Heartlands CCG

Surrey Heartlands CCG

Vale of York CCG

Walsall CCG

West Sussex

West Sussex CCG

References

- A. The Liothyronine Dossier Case Details with Clear Evidence that NHS England Guidance on Prescription of Liothyronine is not Being Followed by CCGs, October 2018
<https://www.thyroidtrust.org/liothyronine-dossier-2018.html>
- B. The T3 Prescribing Survey Report, February 2020
https://www.thyroidtrust.org/uploads/3/1/8/1/31816005/t3_prescribing_survey_report_7.2.20.pdf
1. From the Medicines Value Programme: Items which should not be routinely prescribed in primary care: Guidance for CCGs, November 2017
<https://www.england.nhs.uk/publication/items-which-should-not-be-routinely-prescribed-in-primary-care-guidance-for-ccgs/>
 2. NHSE Regional Medicines Optimisation Committee (RMOC) guidelines [RMOC Liothyronine Guidance June 2019](#)
 3. NICE NG145 Guideline Thyroid Disease: Assessment and Management NHS England [NICE NG145 Guidance November 2019](#)
 4. Lord Bethell statement regarding further guidance from NHS England [Parliament-Lords Written Question Liothyronine 12.2.2020](#)
 5. Norfolk and Waveney CCG liothyronine patient pathway [Norfolk & Waveney CCG Liothyronine Pathway Approved May 2020](#)
 6. NICE guideline and RMOC liothyronine guidance – how to find the reference to the RMOC prescribing guidance in the NICE guideline for thyroid disease assessment and management.
https://www.thyroidtrust.org/uploads/3/1/8/1/31816005/nice_and_liothyronine.pdf

With thanks to Helga Taylor, research volunteer, and all the thyroid patients and clinicians who have contributed information and worked hard to address this issue over the last several years.

The Thyroid Trust

www.thyroidtrust.org

connect@thyroidtrust.org

Registered charity number 1183292

Registered office: 15 Great College Street, London, SW1P 3RX